View in EDS

Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.

Saved in:
Bibliographic Details
Title: Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.
Authors: Gerber DE; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas., Infante JR; Janssen Pharmaceuticals, Inc., Raritan, New Jersey., Gordon MS; HonorHealth Research Institute, Scottsdale, Arizona., Goldberg SB; Yale School of Medicine, New Haven, Connecticut., Martín M; Instituto De Investigacion Sanitaria Gregorio Marañon, Ciberonc, Universidad Complutense, Madrid, Spain., Felip E; Vall d'Hebron Institute of Oncology, Barcelona, Spain., Martinez Garcia M; Hospital del Mar, Barcelona, Spain., Schiller JH; Inova Fairfax Hospital, Annandale, Virginia., Spigel DR; Sarah Cannon Research Institute, Nashville, Tennessee., Cordova J; Genentech, Inc., South San Francisco, California., Westcott V; Genentech, Inc., South San Francisco, California., Wang Y; Genentech, Inc., South San Francisco, California., Shames DS; Genentech, Inc., South San Francisco, California., Choi Y; Genentech, Inc., South San Francisco, California., Kahn R; Genentech, Inc., South San Francisco, California., Dere RC; Genentech, Inc., South San Francisco, California., Samineni D; Genentech, Inc., South San Francisco, California., Xu J; Genentech, Inc., South San Francisco, California., Lin K; Genentech, Inc., South San Francisco, California., Wood K; Genentech, Inc., South San Francisco, California., Royer-Joo S; Genentech, Inc., South San Francisco, California., Lemahieu V; Genentech, Inc., South San Francisco, California., Schuth E; Genentech, Inc., South San Francisco, California., Vaze A; Genentech, Inc., South San Francisco, California., Maslyar D; Genentech, Inc., South San Francisco, California., Humke EW; Genentech, Inc., South San Francisco, California., Burris HA 3rd; Sarah Cannon Research Institute, Nashville, Tennessee. howard.burris@SarahCannon.com.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Jan 15; Vol. 26 (2), pp. 364-372. Date of Electronic Publication: 2019 Sep 20.
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 31540980
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Gerber+DE%22">Gerber DE</searchLink>; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.<br /><searchLink fieldCode="AU" term="%22Infante+JR%22">Infante JR</searchLink>; Janssen Pharmaceuticals, Inc., Raritan, New Jersey.<br /><searchLink fieldCode="AU" term="%22Gordon+MS%22">Gordon MS</searchLink>; HonorHealth Research Institute, Scottsdale, Arizona.<br /><searchLink fieldCode="AU" term="%22Goldberg+SB%22">Goldberg SB</searchLink>; Yale School of Medicine, New Haven, Connecticut.<br /><searchLink fieldCode="AU" term="%22Martín+M%22">Martín M</searchLink>; Instituto De Investigacion Sanitaria Gregorio Marañon, Ciberonc, Universidad Complutense, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Felip+E%22">Felip E</searchLink>; Vall d'Hebron Institute of Oncology, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Martinez+Garcia+M%22">Martinez Garcia M</searchLink>; Hospital del Mar, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Schiller+JH%22">Schiller JH</searchLink>; Inova Fairfax Hospital, Annandale, Virginia.<br /><searchLink fieldCode="AU" term="%22Spigel+DR%22">Spigel DR</searchLink>; Sarah Cannon Research Institute, Nashville, Tennessee.<br /><searchLink fieldCode="AU" term="%22Cordova+J%22">Cordova J</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Westcott+V%22">Westcott V</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Wang+Y%22">Wang Y</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Shames+DS%22">Shames DS</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Choi+Y%22">Choi Y</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Kahn+R%22">Kahn R</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Dere+RC%22">Dere RC</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Samineni+D%22">Samineni D</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Xu+J%22">Xu J</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Lin+K%22">Lin K</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Wood+K%22">Wood K</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Royer-Joo+S%22">Royer-Joo S</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Lemahieu+V%22">Lemahieu V</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Schuth+E%22">Schuth E</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Vaze+A%22">Vaze A</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Maslyar+D%22">Maslyar D</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Humke+EW%22">Humke EW</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Burris+HA+3rd%22">Burris HA 3rd</searchLink>; Sarah Cannon Research Institute, Nashville, Tennessee. howard.burris@SarahCannon.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502500%22">Clinical cancer research : an official journal of the American Association for Cancer Research</searchLink> [Clin Cancer Res] 2020 Jan 15; Vol. 26 (2), pp. 364-372. <i>Date of Electronic Publication: </i>2019 Sep 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502500 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1557-3265 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210780432%22">10780432 </searchLink><i>NLM ISO Abbreviation: </i>Clin Cancer Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=31540980
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1078-0432.CCR-18-3965
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 364
    Titles:
      – TitleFull: Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gerber DE
      – PersonEntity:
          Name:
            NameFull: Infante JR
      – PersonEntity:
          Name:
            NameFull: Gordon MS
      – PersonEntity:
          Name:
            NameFull: Goldberg SB
      – PersonEntity:
          Name:
            NameFull: Martín M
      – PersonEntity:
          Name:
            NameFull: Felip E
      – PersonEntity:
          Name:
            NameFull: Martinez Garcia M
      – PersonEntity:
          Name:
            NameFull: Schiller JH
      – PersonEntity:
          Name:
            NameFull: Spigel DR
      – PersonEntity:
          Name:
            NameFull: Cordova J
      – PersonEntity:
          Name:
            NameFull: Westcott V
      – PersonEntity:
          Name:
            NameFull: Wang Y
      – PersonEntity:
          Name:
            NameFull: Shames DS
      – PersonEntity:
          Name:
            NameFull: Choi Y
      – PersonEntity:
          Name:
            NameFull: Kahn R
      – PersonEntity:
          Name:
            NameFull: Dere RC
      – PersonEntity:
          Name:
            NameFull: Samineni D
      – PersonEntity:
          Name:
            NameFull: Xu J
      – PersonEntity:
          Name:
            NameFull: Lin K
      – PersonEntity:
          Name:
            NameFull: Wood K
      – PersonEntity:
          Name:
            NameFull: Royer-Joo S
      – PersonEntity:
          Name:
            NameFull: Lemahieu V
      – PersonEntity:
          Name:
            NameFull: Schuth E
      – PersonEntity:
          Name:
            NameFull: Vaze A
      – PersonEntity:
          Name:
            NameFull: Maslyar D
      – PersonEntity:
          Name:
            NameFull: Humke EW
      – PersonEntity:
          Name:
            NameFull: Burris HA 3rd
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 01
              Text: 2020 Jan 15
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-electronic
              Value: 1557-3265
          Numbering:
            – Type: volume
              Value: 26
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Clinical cancer research : an official journal of the American Association for Cancer Research
              Type: main
ResultId 1